Bayer publishes findings on gadoquatrane contrast agent for pediatric use
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 03 2025
0mins
Source: SeekingAlpha
Study Overview: Bayer released data from the QUANTI Pediatric trial, which tested low-dose gadoquatrane, a gadolinium-based MRI contrast agent for children, using a reduced dose of 0.04 mmol Gd/kg body weight.
Trial Results: The trial successfully met its primary endpoint, showing that the pharmacokinetic behavior of gadoquatrane in children was comparable to that observed in adults.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
